Panacea Biotec

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE922B01023
NSEID: PANACEABIO
BSEID: 531349

INR

344.15

-3.05 (-0.88%)

BSENSE

Dec 05

BSE+NSE Vol: 44.74 k

Click here to access the older version

Company CV

About Panacea Biotec Ltd

Panacea Biotec Ltd

Small Cap

Pharmaceuticals & Biotechnology

India's leading research-based health management company with established research, manufacturing and marketing capabilities are collectively known as Panacea Biotec Limited (PBL), which was incorporated on February 2, 1984 under the name of Panacea Drug (P) Ltd.

Company Coordinates

Company Details

Ambala-Chandigarh Highway , Lalru Punjab : 140501

Tel: 91-1762-505900

http://www.panaceabiotec.com

companysec@panaceabiotec.com

Registrar Details

Skyline Financial Services Pvt Ltd , D-153/A, 1st Floor, Okhla Industrial Area, Phase - I, New Delhi

Capital Structure

Present Equity Capital

INR 6.13 Cr

Number of Shares

6.13 Cr

Face Value

INR 1.0

Date

Number
of Shares(Cr)

Equity
Capital (Rs Cr)

Shares Added

Face Value (Rs)

Reason

08-Oct-2010

6.13

-2000

Buy Back of Shares

08-Oct-2010

6.13

-2000

Buy Back of Shares

07-Oct-2010

6.13

-3000

Buy Back of Shares

07-Oct-2010

6.13

-3000

Buy Back of Shares

28-Sep-2010

6.13

-25000

Buy Back of Shares

28-Sep-2010

6.13

-30000

Buy Back of Shares

28-Sep-2010

6.13

-25000

Buy Back of Shares

28-Sep-2010

6.13

-30000

Buy Back of Shares

27-Sep-2010

6.14

-105000

Buy Back of Shares

27-Sep-2010

6.13

-106156

Buy Back of Shares

Shareholding

Shareholding Snapshot

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 2 Schemes (0.0%)

FIIs

Held by 15 FIIs (1.06%)

Promoter with highest holding

Dr. Rajesh Jain (49.33%)

Highest Public shareholder

None

Individual Investors Holdings

17.69%

Board of Directors

Period

Management

Designation

Remuneration

Soshil Kumar Jain

Chairman & Exec. Director

1.15 cr

Rajesh Jain

Chairman & Managing Director

77.7 lacs

Sandeep Jain

Joint Managing Director

72.1 lacs

R L Narasimhan

Non-Exec. & Independent Dir.

3.3 lacs

N N Khamitkar

Non-Exec. & Independent Dir.

3.1 lacs

K M Lal

Non-Exec. & Independent Dir.

3.3 lacs

Vinod Goel

Group CFO & Company Secretary

Manjula Upadhyay

Non-Exec. & Independent Dir.

2.5 lacs

Mukul Gupta

Non-Exec. & Independent Dir.

2.5 lacs

Ankesh Jain

Whole-time Director

27.7 lacs

BHUPINDER SINGH

Non-Exec. & Independent Dir.

2.5 lacs

Narotam Kumar Juneja

Director

Raw Materials

Raw Materials Dashboard

Raw Materials

Amount(Rs Cr)

% of RM Cost

No Data Available for Raw Material Segmentation

No Data Available

Finished Goods

Finished Goods Dashboard

Finished Goods

Amount(Rs Cr)

% of Sales Turnover

Formulations and Vaccines

516.04

88.98%

Traded Goods

40.43

6.97%

Other Operating Revenue - Research and License Fees

11.04

1.90%

Formulations and Vaccines

Traded Goods

Other Operating Revenue - Research and License Fees

Stock DNA

Revenue and Profits:

Net Sales:

141 Cr

(Quarterly Results - Sep 2025)

Net Profit:

-14 Cr

Industry

Pharmaceuticals & Biotechnology

Market cap

INR 2,128 Cr (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.08

Return on Equity

-5.72%

Price to Book

2.56